U.S. Markets close in 3 hrs 27 mins
  • S&P 500

    4,265.64
    +23.80 (+0.56%)
     
  • Dow 30

    34,112.39
    +238.15 (+0.70%)
     
  • Nasdaq

    14,399.83
    +128.10 (+0.90%)
     
  • Russell 2000

    2,319.16
    +15.69 (+0.68%)
     
  • Crude Oil

    73.03
    -0.05 (-0.07%)
     
  • Gold

    1,778.30
    -5.10 (-0.29%)
     
  • Silver

    26.08
    -0.03 (-0.12%)
     
  • EUR/USD

    1.1936
    +0.0003 (+0.0239%)
     
  • 10-Yr Bond

    1.4900
    +0.0030 (+0.20%)
     
  • Vix

    15.77
    -0.55 (-3.37%)
     
  • GBP/USD

    1.3916
    -0.0047 (-0.3382%)
     
  • USD/JPY

    110.8500
    -0.1120 (-0.1009%)
     
  • BTC-USD

    33,990.49
    +275.08 (+0.82%)
     
  • CMC Crypto 200

    821.52
    +34.90 (+4.44%)
     
  • FTSE 100

    7,109.97
    +35.91 (+0.51%)
     
  • Nikkei 225

    28,875.23
    +0.34 (+0.00%)
     

FIBROGEN INVESTOR ALERT: June 11, 2021 Deadline for Seeking Appointment as Lead Plaintiff In Securities Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN)

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

San Francisco, California--(Newsfile Corp. - May 14, 2021) - On April 12, 2021, Berman Tabacco's California office filed a class action lawsuit for violations of the federal securities laws against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN), and certain of its current and former officers and directors, on behalf of all other persons and entities who purchased or otherwise acquired FibroGen securities and/or sold put options from November 8, 2019, through and including April 6, 2021.

The lawsuit was filed in U.S. District Court in the Northern District of California and asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, 15 U.S.C. §§78j(b) and 78t(a). The case is captioned Xu v. FibroGen, Inc., et al., No. 3:21-cv-02623. A copy of the complaint is available on the firm's website.

On May 6, 2021, a follow-on case was filed in the Northern District of California extending the class period from October 18, 2017 through April 6, 2021.

If you wish to serve as Lead Plaintiff for the Class, you must file a motion to serve as Lead Plaintiff with the Court no later than June 11, 2021. Any member of the proposed Class may either move the Court to serve as Lead Plaintiff through counsel of their choice, or choose to do nothing and remain a member of the proposed Class.

If you have significant losses from your purchases of FibroGen securities and/or sold put options during the period from October 18, 2017 to April 6, 2021, and wish to discuss the process for seeking appointment as Lead Plaintiff, please visit: https://bit.ly/3wSuqJf.

Berman Tabacco is a national law firm representing institutions and individuals in lawsuits, seeking to recoup losses caused by corporate and board misconduct and violations of the securities and antitrust laws. The firm has offices in San Francisco, California and Boston, Massachusetts.

This notice may constitute attorney advertising.

Contact:
Jeffrey Miles, Esq.
(800) 516-9926
Email: law@bermantabacco.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/84152